Based on the cost-benefit analysis performed by FDA , the rule will impose an unfunded mandate on the private sector of over $ 100 million annually and therefore the rule is subject to the requirements of the Act .
The FDA insisted on doing a cost-benefit analysis before and rules were imposed on the private sector .